KholleKhokk

QD - Chinese Microloan Unicorn. +100% upside potential

KholleKhokk 업데이트됨   
NYSE:QD   Qudian Inc.
1. ER report +320% earnings growth (want played out)

2. Traders are scared of "data leak"+"regulation" will bring company down to zero. Thats why company lost 30% valuation on premarket. And got back to -3% in same day.

3. China wants to regulate "micro-loan industry". That was played out bearish, but it is actually bullish. China wants to BAN small and bad companies - competitors of QD. Means more profits for QD in future.

4. No serious risks in China Crysis in near term future (look at Tencent earnings report), economics might actually boost from here and now.

This will eventually end up 30+. When? don't know, but i think here is the bottom.
코멘트:
-13% at premarket on the fact, that it complies to regulation and changes its credits to 24% effective rate annualized instead of 36%.

And this still played out bearish, because of future earnings will be lower.
But now we all know that company will do everything (and fast) to present on the market as a leader. I still think thats an opportunity.

Will try to Buy this after downgrades.

Current Price Targets are irrelevant:

Nov-20-17 Initiated Needham Buy $30
Nov-15-17 Initiated Stifel Buy $35
Nov-15-17 Initiated Morgan Stanley Equal-Weight $28.70
Nov-14-17 Initiated Macquarie Outperform $36
코멘트:
Another -25% down.
China gov. will make a statement this week about the whole microloan industry.

First downgrades came out:
Nov-24-17 Reiterated Macquarie Outperform $36 >> $24 (ha ha, with credit rate slash from 36%/y to 24%/y)

Waiting for more downgrades to come + "sell the rumors buy the facts" thing.

Still waiting to buy, no reversal seen on the chart.
코멘트:
One more downgrade:

Stifel analyst, John Davis, reiterated his Buy rating on shares of Qudian (NYSE: QD) but cut his price target to $19 from $35
액티브 트레이드
코멘트:
Back to 16! Volumes are pretty small though!
코멘트:
great ER report. hold

면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.